CFGS
HUMA icon

Concourse Financial Group Securities’s Humacyte HUMA Stock Holding History

Concourse Financial Group Securities’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$4.59K – 945
2024
Q4 		$4.59K Hold
1,000
– – ﹤0.01% 1897
2024
Q3 		$5.44K Hold
1,000
– – ﹤0.01% 1845
2024
Q2 		$4.8K Buy
+1,000
New +$5.21K ﹤0.01% 1878

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Concourse Financial Group Securities's HUMA Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Humacyte (HUMA) in Q1 2025, closing a stake of 1,000 shares — an estimated $4.59K sold.

Concourse Financial Group Securities first reported a position in HUMA in Q2 2024 and held it in 3 quarters. The position peaked at $5.44K in Q3 2024. 168 funds tracked by Wall St. Rank hold HUMA as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining Humacyte position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 1,000 Humacyte shares in Q1 2025, an estimated $4.59K.
  • Concourse Financial Group Securities first reported a position in Humacyte in Q2 2024 and held it in 3 quarters.
  • Concourse Financial Group Securities's Humacyte position peaked at $5.44K in Q3 2024.
  • 168 funds tracked by Wall St. Rank held Humacyte as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.